1. Home
  2. TLIH vs NEUP Comparison

TLIH vs NEUP Comparison

Compare TLIH & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TLIH

Ten-League International Holdings Limited Ordinary Shares

N/A

Current Price

$0.41

Market Cap

11.8M

Sector

N/A

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.91

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLIH
NEUP
Founded
1998
1996
Country
Singapore
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
10.3M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
TLIH
NEUP
Price
$0.41
$3.91
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
396.2K
82.1K
Earning Date
09-30-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$51,204,304.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$2.90
52 Week High
$7.00
$21.40

Technical Indicators

Market Signals
Indicator
TLIH
NEUP
Relative Strength Index (RSI) N/A 37.32
Support Level N/A $3.79
Resistance Level N/A $4.15
Average True Range (ATR) 0.00 0.25
MACD 0.00 0.11
Stochastic Oscillator 0.00 13.95

Price Performance

Historical Comparison
TLIH
NEUP

About TLIH Ten-League International Holdings Limited Ordinary Shares

Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: